In patients from Asia with previously treated advanced HCC, pembrolizumab significantly prolonged overall survival and PFS, and ORR was greater versus placebo.

Bookmark

View Full Paper

Bookmark

View Full Paper

Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III Trial | Synapse

Cite This Study

Qin et al. (Thu,) studied this question.

synapsesocial.com/papers/69d76dbdf44a16d01ef30f58 https://doi.org/https://doi.org/10.1200/jco.22.00620

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1O-1 Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma2021 · 29 citations
2

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1O-1 Results from a global phase 2 study of tislelizumab, an investigational PD-1 antibody, in patients with unresectable hepatocellular carcinoma2021 · 29 citations
2

Epidemiological differences of common liver conditions between Asia and the West

2019 · 38 citations

3Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up2014 · 2,259 citations

4Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial2018 · 2,536 citations

5Toxicity and response criteria of the Eastern Cooperative Oncology Group1982 · 11,627 citations